Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.
Epistemonikos ID: 40003a54d2fffbe7bdb7abdfd557cb815a0bd931
First added on: May 09, 2024